Qilian International Holding Group Limited logo

Qilian International Holding Group LimitedNASDAQ: QLI

Profile

Sector:

Healthcare

Country:

China

IPO:

12 January 2021

Next earnings report:

05 July 2024

Last dividends:

27 February 2023

Next dividends:

N/A
$30.03 M
-80%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
-75%vs. 3y high
33%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 02 Jul 2024 23:15:53 GMT
$4.20+$0.35(+9.09%)
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

QLI Latest News

Qilian International plans to adjust industrial investment
prnewswire.com17 May 2024 Sentiment: NEGATIVE

Qilian International Holdings Group Limited, a pharmaceutical and chemical products manufacturer based in China, has faced difficulties in the past two years due to decreasing demand and prices for its oxytetracycline products, as well as rising environmental standards. These challenges have resulted in higher production and operational costs, impacting the profitability of the oxytetracycline industry.

What type of business is Qilian International Holding Group Limited?

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

What sector is Qilian International Holding Group Limited in?

Qilian International Holding Group Limited is in the Healthcare sector

What industry is Qilian International Holding Group Limited in?

Qilian International Holding Group Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is Qilian International Holding Group Limited from?

Qilian International Holding Group Limited is headquartered in China

When did Qilian International Holding Group Limited go public?

Qilian International Holding Group Limited initial public offering (IPO) was on 12 January 2021

What is Qilian International Holding Group Limited website?

https://www.qlsyy.net

Is Qilian International Holding Group Limited in the S&P 500?

No, Qilian International Holding Group Limited is not included in the S&P 500 index

Is Qilian International Holding Group Limited in the NASDAQ 100?

No, Qilian International Holding Group Limited is not included in the NASDAQ 100 index

Is Qilian International Holding Group Limited in the Dow Jones?

No, Qilian International Holding Group Limited is not included in the Dow Jones index

When does Qilian International Holding Group Limited report earnings?

The next expected earnings date for Qilian International Holding Group Limited is 05 July 2024